David Calkins

Professor at the Department of Ophthalmology and Visual Sciences at Vanderbilt University, David Calkins is a distinguished researcher dedicated to understanding the molecular mechanisms underlying neurodegeneration in the visual pathways. His work is pivotal in elucidating how the retina and optic nerve, which are the primary central nervous system components responsible for transmitting visual information to the brain, function in both health and disease. Professor Calkins' research is particularly focused on the effects of aging on these visual components, exploring how they become vulnerable to conditions such as glaucoma, macular degeneration, and non-arteritic anterior optic neuropathy. His investigations aim to uncover the intricate cascades and pathways that influence the sensitivity and susceptibility of these components to stressors associated with glaucoma, including age and ocular pressure. Through his research, Professor Calkins seeks to advance the understanding of neurodegenerative diseases affecting the visual system. His work is instrumental in identifying potential therapeutic targets that could mitigate the progression of these diseases, thereby preserving vision and improving the quality of life for affected individuals. At Vanderbilt University, Professor Calkins is not only a leading researcher but also a dedicated educator, mentoring the next generation of scientists and clinicians in the field of ophthalmology and visual sciences. His contributions to the field are widely recognized, and he continues to collaborate with fellow researchers to push the boundaries of knowledge in neurodegenerative visual disorders. In addition to his academic pursuits, Professor Calkins actively participates in various professional organizations and conferences, sharing his findings and engaging with the broader scientific community. His commitment to advancing the field of ophthalmology is evident in his ongoing efforts to translate research discoveries into practical applications that can benefit patients worldwide.